Monotherapy with ipilimumab, an anti-CTLA4 monoclonal antibody, at 3 mg/kg, 3 weekly dosing failed to show any response in 27 patients in a phase II trial [84], whilst a phase I pan-tumour study of an anti-PD-L1 antibody included 14 patients with pancreatic cancer, with none exhibiting an objective response [85]. The gene discussed is CTLA4; the disease is pancreatic neoplasm.